US20050042237A1 - Method for administering a spill resistant pharmaceutical system - Google Patents

Method for administering a spill resistant pharmaceutical system Download PDF

Info

Publication number
US20050042237A1
US20050042237A1 US10653149 US65314903A US2005042237A1 US 20050042237 A1 US20050042237 A1 US 20050042237A1 US 10653149 US10653149 US 10653149 US 65314903 A US65314903 A US 65314903A US 2005042237 A1 US2005042237 A1 US 2005042237A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
spill
spoon
formulation
sodium
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10653149
Inventor
Rakesh Mehta
Dan Moros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceutical Industries Ltd
Original Assignee
Taro Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015Devices specially adapted for taking medicines
    • A61J7/0023Spoons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015Devices specially adapted for taking medicines
    • A61J7/0053Syringes, pipettes or oral dispensers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015Devices specially adapted for taking medicines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Abstract

A method for administering a spill-resistant pharmaceutical formulation comprises delivery from a squeezable container of a pharmaceutical agent in a suitable vehicle comprising a liquid base and a thickening agent.

Description

    BACKGROUND OF THE INVENTION
  • [0001]
    This application is a continuation of U.S. Ser. No. 10/052,462, now issued, filed on Jan. 23, 2002 which is a divisional of U.S. Ser. No. 09/549,148, now U.S. Pat. No. 6,399,079, filed on Apr. 13, 2000, which is a continuation of U.S. Ser. No. 09/089,360 now U.S. Pat. No. 6,071,523, filed on Jun. 3, 1998, all of which are hereby incorporated by reference.
  • [0002]
    The invention relates to compositions for administering pharmaceuticals orally without spilling. More specifically, the invention relates to vehicles and devices for delivering a variety of pharmaceutical products.
  • [0003]
    Syrups, elixirs, solutions, and suspensions are traditional dosage forms for oral medication. These liquid formulations are typically measured by pouring into a spoon, but this approach has the great drawback of spillage. The risk of spillage can cause people to underfill the spoon, leading to inaccurate dosage. With elderly people, children, and the infirm, difficulty in filling a spoon with a liquid and bringing it to the mouth can be a serious impediment to administering the medicine. Solid formulations such as pills, tablets, and capsules are also difficult for children and for elderly, infirm people to swallow.
  • [0004]
    Tachon et al., U.S. Pat. No. 5,300,302, teaches a pump dispenser for administering a metered dosage of a drug formulation. This requires a complex mechanical device and formulation properties suitable for pumping.
  • [0005]
    Gorman et al., U.S. Pat. No. 5,288,479, teaches a thickened pharmaceutical preparation comprising a hexitol and a seaweed polysaccharide. Such compositions tend to separate, and require a metered dispenser.
  • [0006]
    Ross, U.S. Ser. No. 08/114,315, EP 95939059.2 (commonly owned with this application and incorporated herein by reference), teaches semi-solid formulations and a delivery system. However, there remains a need for more stable compositions with improved Theological characteristics. There is also a need for a reliable test system for identifying optimal formulations.
  • SUMMARY OF THE INVENTION
  • [0007]
    The invention relates to a drug delivery system including combination of a squeezable container, a dispenser, and a semi-solid pharmaceutical formulation. Each of these elements of the drug delivery system has certain characteristics so that the combination (a) allows easy administration (b) of a measured amount of the drug, (c) from a convenient, preferably tamper-resistant and child-proof container, (d) with predetermined resistance to spilling, (e) while providing a suitable storage stable pharmaceutical composition with compatible components. These properties result from a variety of physico-chemical characteristics of the formulation optimized in conjunction with the type of container and dispenser.
  • [0008]
    An embodiment of the invention is a method for obtaining a suitable spill-resistant formulation comprising combining a systemic pharmaceutical agent suitable for oral administration with a semi-solid vehicle, and then conducting the following tests of the formulation: measuring initial viscosity, measuring yield value, extruding the formulation into a spoon from a container through a 1 to 5 mm orifice, observing the spreading/leveling characteristic of the formulation in the spoon, measuring spill resistance by spill start time after at least one of spoon vibration, spoon inversion, and spoon tilting at 90 degrees, and measuring viscosity after storing at elevated temperature for at least one month.
  • [0009]
    The compositions of the invention are light, water-soluble gels, which are easy to clean from a spoon bowl, and from any other surfaces which they may contact. The surface tensions of the formulations are sufficiently high to provide desirable spill-resistance, while allowing the product to be sufficiently free-flowing. In the examples of the prior Ross application, the viscosity was higher, providing a firm, spill-proof product. Here, the range of viscosity is lower, providing a freer-flowing, better leveling product, that is easier to administer with spill-resistance, but one which is more prone to spillage than the prior formulations. Thus, while the prior compositions may be considered spill-proof, the compositions set forth here are optimally “spill-resistant” but have other superior characteristics e.g. as to measurability and dispensability.
  • [0010]
    Preferred characteristics for the formulation and the method are as follows. The viscosity, when measured by a Brookfield Viscometer using “C” spindle at 20 rpm and 20-25 degrees Celsius, is between about 5,000 to 50,000 cps, preferably less than 25,000-2cps. Surprisingly, a most preferred range for a formulation to be squeezed from a tube is between about 7,000 and about 12,500 cps. The formulation does not start to spill until after about 30 seconds when vibrated at a frequency of about 2-8 per second, and an amplitude up to about 1 inch. The spill start time on spoon inversion is at least about 20-30 seconds for a plastic 8 ml spoon, longer than for a syrup, and within about 1-20 seconds on spoon tilting at 90 degrees, which is slower than a syrup, but faster than prior non-spill formulations.
  • [0011]
    Preferred compositions have good shelf life, meaning that the preferred characteristics are retained after at least three months storage at a temperature of at least about 40 degrees Celsius at 75% humidity, which extrapolates under normal assumptions accepted by the U.S. Food and Drug Administration to two years shelf-life stability at room temperature. Surprisingly, in preferred embodiments using carboxyvinyl polymers such as Carbopol 974, stability may be accomplished by minimizing sodium containing substances from the formulation. Also, the Carbopol has a surprising taste masking effect for bitter drugs like acetaminophen.
  • [0012]
    Preferred compositions have Carbopol 974 in a concentration of from about 0.25% to below about 1%, in contrast to prior compositions having 1% or more. Other preferred compositions have a cellulose derivative in an amount of from about 2.5% to 3.3%, more preferably less than about 2%. A particularly preferred composition has about 1% microcrystalline cellulose and less than about 2.0% sodium carboxymethylcellulose, in contrast to prior formulations with about 2.4 to 2.8% CMC.
  • [0013]
    The configuration of the container, closure device, and receptacle and the consistency of the formulation are selected so that in response to pressure on the container when the channel closure device is open, a single predetermined unit dose of the pharmaceutical composition can be easily squeezed by manual pressure from the container through the channel into the receptacle, measured, and administered orally without spilling any of the composition from the container or the receptacle. The device may be as shown in the commonly owned Ross application or any other suitable device available to a person of ordinary skill.
  • [0014]
    This invention succeeds where previous efforts failed to provide a simple, stable, useful system of spill-resistant pharmaceutical formulations. This invention solves a previously unrecognized problem as to the Theological properties that must be optimized for a successful spill-resistant formulation.
  • [0015]
    This invention is in a crowded and mature art of oral medications, in which new dosage forms are constantly sought, at great expense and at high profit. Nonetheless, no similar composition or system has been previously discovered. Indeed, semi-solid formulations run contrary to the conventional wisdom of using either liquid or solid dosage forms.
  • [0016]
    This invention omits complex mechanical elements employed in the prior art such as pumps, syringes, and elaborate measuring vessels without loss of ability, and indeed with improved performance. This provides advantages in manufacturing, distribution, and waste disposal, and other economies as well.
  • [0017]
    The drug delivery system of the invention is counter-intuitive and inventive as indicated by the lack of commercially available embodiments of semi-solid formulations for oral administration of pharmaceutical agents. The resistant drug delivery system of the invention solves such longstanding problems with liquid formulations as spillage, and resultant underfilling of measuring spoons. The drug delivery system of the invention also overcomes the disadvantages of solid dosage forms, such as being hard to swallow.
  • [0018]
    The inventive formulations are semi-solid, not liquid or solid. Palatability, stability (a long shelf life) compatibility of components, and ease of administration of a required dose are provided. The system allows effortless administration of predetermined measured doses to children and adults with motor problems, without spilling. It is easier to measure than a liquid and easier to swallow than a solid.
  • [0019]
    A spill-resistant pharmaceutical formulation for oral administration from a squeezable container comprises a per-unit dose effective amount of a pharmaceutical agent in a suitable vehicle comprising a liquid base and a thickening agent, the formulation consisting of mutually compatible components and having the following properties: a viscosity within the range of about 7500 to about 25,000 cps using a Brookfield Viscometer with a ‘C’ spindle with Helipath movement at a spindle speed of 20 rpm and 20-25° C.; a viscometric yield value of a semi-solid; a spill-resistant consistency permitting the composition to be squeezed by light manual pressure through a channel of about 1-5 mm, to spread in a spoon bowl sufficiently quickly for accurate measurement, and to remain in the spoon bowl without spilling for at least several seconds on spoon inversion and tilting at 90 degrees, and for at least one minute upon spoon vibration; homogeneity such that the components do not separate under conditions of use, and a storage stability such that the foregoing properties are retained for at least three months of storage at accelerated stability conditions of elevated temperature and humidity.
  • [0020]
    The viscosity is preferably between about 7000 and about 25,000 cps, more preferably between about 7500 and about 12,500 cps, after storage for three months at a temperature of at least 40 degrees C.
  • [0021]
    The formulation preferably comprises about 0.25 to about 1% water-soluble carboxyvinyl polymer and is preferably essentially free of sodium. The liquid base preferably comprises glycerin and sorbitol, and the thickening agent preferably comprises sodium carboxymethylcellulose in an amount of less than about 2.5% and microcrystalline cellulose in an amount of about 0.9%. The formulation preferably comprises glycerin and sorbitol as a solution of about 70% in water, the concentration of glycerin and sorbitol solution being about 40%, and microcrystalline cellulose in an amount of about 0.9%, and carboxymethylcellulose in an amount of about 0.9% to about 2.4%.
  • [0022]
    The pharmaceutical agent is preferably selected from the group consisting of an analgesic, non-steroidal anti-inflammatory, antihistamine, cough suppressant, expectorant, bronchodilator, anti-infective, CNS active drug, cardiovascular drug, antineoplastic, cholesterol-lowering drug, anti-emetic, vitamin, mineral supplement and fecal softener. The pharmaceutical agent may be selected from the group consisting of acetaminophen, aspirin, ibuprofen, diphenhydramine, dextromethorphan, guafenesin, pseudoephedrine, carbidopa, levodopa, terfenadine, ranitidine, ciprofloxacin, triazolam, fluconazole, propranolol, acyclovir, fluoxetine, enalapril, diltiazem, lovastatin and a pharmaceutically acceptable salt or ester thereof.
  • [0023]
    The liquid base is preferably in an amount of about 45 weight-percent to about 95 weight-percent, comprising a palatable solvent, selected from the group consisting of water, propylene glycol, polyethylene glycol, glycerin, and mixtures thereof, and the thickening agent is preferably in an amount of about 1 weight-percent to about 55 weight-percent, and is selected from the group consisting of starch, modified starch, sodium carboxymethyl cellulose in an amount of less than about 2%, microcrystalline cellulose, hydroxypropyl cellulose, other cellulose derivatives, acacia, tragacanth, pectin, gelatin, polyethylene glycol, and water-soluble carboxyvinyl polymers in a concentration of less than 1% and in the absence of a sodium component. The thickening agent is preferably a cellulose derivative in an amount of about 0.9 to 2.5 weight % by volume.
  • [0024]
    The invention further encompasses a pharmaceutical delivery system comprising the formulation of the invention in a squeezable container from which a unit dose of the formulation may be squeezed, either a single dose or multiple doses of the formulation. The system may further comprise a spoon bowl receptacle attachable to the container.
  • [0025]
    A method for producing a formulation for a spill-resistant pharmaceutical composition comprises combining a per-unit dose effective amount of a pharmaceutical agent with suitable vehicle components comprising a liquid base and a thickening agent, testing the formulation for acceptance criteria for a composition that can be easily squeezed from a container into a receptacle, measured, and administered orally without spilling the composition from the container or the receptacle, and accepting a formulation that satisfies the acceptance criteria, the acceptance criteria comprising:
      • viscosity within the range 2500-75,000, preferably 5000-45,000 cps equivalent using a Brookfield Viscometer with a ‘C’ spindle with Helipath movement at 20 RPM and 20-25° C.;
      • viscometric yield value,
      • ease of administration comprising (a) extrudability under light manual pressure from a squeezable container or a proxy (e.g. a syringe with a 5 mm orifice), and (b) spreadability in a spoon bowl measured by extruding the formulation into a spoon bowl and determining whether the material spreads to the edges of the spoon bowl,
      • spill resistance in the spoon bowl during at least one test period of vibrations, inversion, and tilting, while monitoring whether the product spills from the spoon,
      • mutual compatibility of the components such that they do not separate, and
      • shelf-life of two years at room temperatures as demonstrated by 3-months accelerated stability testing at elevated temperature and humidity.
  • [0032]
    The test spoon may be plastic and the test period for vibrations at least about five minutes, the test period for inversion at least about 30 seconds, and the test period for tilting at least about 20 seconds. The spreadability is such that the formulation spreads to the edge of the spoon within seconds. The method preferably comprises testing a vehicle without the pharmaceutical agent for at least one of the acceptance criteria, combining the pharmaceutical agent with the vehicle, and then testing the formulation for all acceptance criteria.
  • [0033]
    Further objectives and advantages will become apparent from a consideration of the description and drawings.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0034]
    The invention is better understood by reading the following detailed description with reference to the accompanying figures, in which like reference numerals refer to like elements throughout, and in which:
  • [0035]
    FIGS. 1-4 were included in the commonly-owned Ross application.
  • [0036]
    FIG. 1 illustrates a closed tube containing a semisolid composition of the invention
  • [0037]
    FIG. 2 illustrates a replacement cap of the invention for the tube of FIG. 1 equipped with a spoon for measuring and administering a dose of the semisolid composition of the invention.
  • [0038]
    FIG. 3 illustrates a tube containing the semisolid composition of the invention with attached replacement cap equipped with a spoon.
  • [0039]
    FIG. 4 shows a section of FIG. 3 along lines 4-4.
  • [0040]
    FIG. 5 illustrates inventive test equipment. FIG. 5A shows an apparatus for measuring spill resistance on vibration. FIG. 5B illustrates an apparatus for measuring spill resistance on tilting at 90 degrees.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • [0041]
    In describing preferred embodiments of the present invention illustrated in the drawings, specific terminology is employed for the sake of clarity. However, the invention is not intended to be limited to the specific terminology so selected, and it is to be understood that each specific element includes all technical equivalents which operate in a similar manner to accomplish a similar purpose.
  • [0042]
    Oral drug delivery systems are typically either liquid or solid dosage forms. The invention provides a new system combining a squeezable container and a semisolid oral dosage formulation. There has been a longstanding need for such a system, and there is nothing like it available. This system includes a formulation that has certain physico-chemical and Theological characteristics: such a formulation is (a) semisolid, (b) spill-resistant, (c) easy to administer and measure, (d) storage stable, (e) comprised of compatible components, and (f) has viscosity within a specific range. The meaning of these terms is apparent to one experienced with drug formulation, and as defined herein.
  • [0043]
    Viscosity is measured using a Brookfield Viscometer with a ‘C’ spindle with Helipath movement at 20 RPM and 20-25° C., or equivalent. Viscosity decreases slightly with increasing temperature. It has been noted that viscosity measured at 10 rpm may be significantly higher (50-100%) than measured at 20 rpm; however for some of the formulations, it is impossible to measure the viscosity accurately at the slower spindle speed. It was therefore determined that the 20 rpm spindle speed gave a better reflection of the important rheologic properties of the inventive formulations.
  • [0044]
    Semi-solid character is used to indicate a formulation that has a viscometric yield value determined as a relative value, e.g using the shutting off motion of a Brookfield Viscometer with dial gauge.
  • [0045]
    Ease of administration is intended to mean (a) extrudability under light manual pressure from a squeezable container or a proxy (e.g. a syringe with a 5 mm orifice), and (b) spreadability in a spoon bowl measured by extruding the formulation into a spoon bowl and determining whether the material spreads to the edges of the spoon bowl.
  • [0046]
    Spill resistance is meant as something different than non-spill characteristics. A spill-resistant formulation according to the invention begins to spill from a spoon bowl during test periods of vibrations, inversion, and tilting, but slowly enough to conform with practical time limits between dispensing and ingesting, and quickly enough to enable the product to be readily consumed from a spoon bowl.
  • [0047]
    Mutual compatibility of the components means that they do not separate in preparation and storage for the equivalent of two years at room temperature (as indicated by three-months accelerated stability testing at 40° centigrade and 75% relative humidity). Storage stability means that the materials do not lose their desirable properties during storage for the same period. Preferred compositions do not exhibit a drop in viscosity of more than 50% or an increase in viscosity of more than 100% during that period.
  • [0048]
    Only certain formulations may be prepared to have the physico-chemical and rheological characteristics described herein rendering them suitable for the drug delivery system of the application. Other formulations lack the critical characteristics and are therefore distinct.
  • [0049]
    Criteria for selecting formulations according to the invention included the following:
      • they are semi-solid, in that they have a viscometric yield value determined as a relative value, e.g using the shutting off motion of a Brookfield Viscometer with dial gauge.
      • They are easy to administer—they were easily squeezed from a tube into a teaspoon with light manual pressure such as could be applied by an elderly or infirm person; they tended to level themselves in the spoon by spreading to the edge of the spoon to allow accurate measurement of a teaspoon dose; they did not spill quickly when the spoon was shaken, tipped, or inverted; and they had a consistency making them readily removed orally from the spoon (when a subject inserted the spoon into his mouth, closed his lips, and removed the spoon).
      • They are spill-resistant—this characteristic was quantified in experiments emulating the behavior of elderly, infirm, and young people, in which full teaspoon samples of the formulations were shaken, tilted, and inverted.
      • They are storage-stable for an extended period, without any evidence of separation, hardening, or softening; they retain their preferred viscosity range.
  • [0054]
    They have attractive appearance, suitable texture and mouthfeel.
      • The components are mutually compatible in that they do not interfere with the bioactivity of the pharmaceutical agent or physical properties of the vehicle, and the components do not separate and retain their properties.
      • The formulations are suitable for a squeezable container such as a tube, and for extrusion into a receptacle such as a spoon bowl. The receptacle is sized to hold a unit dose, to hold it conveniently without spilling, and to be comfortable and provide a good fit into the mouth between the lips for oral administration. The oval sectional shape of a typical teaspoon bowl as evolved over history satisfies these criteria and is a suitable receptacle, although other shapes can work as well.
  • [0057]
    These properties complement the characteristics of a simple preferably tamper-resistant and childproof dispensing system for a storage stable, semi-solid, spill-resistant oral systemic pharmaceutical that is easy to administer and measure.
  • EXAMPLES
  • [0058]
    To compare the drug delivery system of the invention to other technologies, experiments were conducted with the goal of identifying and quantifying the relevant physico-chemical characteristics of formulations according to the invention. These were compared to characteristics of other formulations that are commercially available or disclosed in the prior art. The results indicate that the properties of the pharmaceutical compositions herein have surprising advantages and critical characteristics necessary for a non-spill drug delivery system and that the other tested products are unsatisfactory for this system.
  • [0059]
    Materials and Methods
  • [0060]
    TEST SAMPLES (Examples 21 to 31): Laboratory scale (100 g-500 g) batches of pharmaceutical formulations were prepared essentially according to the methods and compositions described in examples 2-4, 7, 9, 11-13, 15-16, and 18 of the earlier Ross application, U.S. Ser. No. 08/114,315. These compositions were tested for the new acceptance criteria set forth herein.
  • [0061]
    These formulations have liquid bases in a concentration of from about 45% to about 97%, and thickeners in the range of 1% for Carbomer, 2-3% for cellulose derivative, or 45% for polyethylene glycol (PEG).
  • S.N. 21 EXAMPLE 2 Pseudoephedrine HCl Formulation Thickened with Polyethylene Glycols
  • [0062]
    Ingredient %
    Pseudoephedrine HCl 0.6
    Propylene Glycol 25.0
    Polyethylene Glycols 73.5
    (PEG 400:PEG 3350 3:1)
    Methyl Paraben 0.22
    Sodium Saccharin 0.20
    Strawberry Flavor 0.05
    D&C Red #33 0.0057
    Purified water to 100
  • [0063]
    PEG with a molecular weight less than 800 is a solid and works as a thickener and over 800 is a liquid. Thus, in S.N. 21, about 18% of the formulation is PEG 3350 (a liquid) and about 55.5% is PEG 400 (a thickener).
  • S.N. 22 EXAMPLE 3 Acetaminophen Formulation Thickened with Carboxymethylcellulose
  • [0064]
    Ingredient %
    Acetaminophen 3.2
    Glycerin 4.0
    Propylene Glycol 25.0
    Sodium Saccharin 0.2
    Methyl Paraben 0.22
    Sodium Carboxymethylcellulose 2.4
    Purified water to 100
  • S.N. 23 EXAMPLE 4 Dextromethorphan Hydrobromide Formulation Thickened with Carbomer
  • [0065]
    Ingredient %
    Dextromethorphan HBr 0.3
    Propylene Glycol 25.0
    Glycerin 4.0
    Carbomer 974P 1.0
    Strawberry Flavor 0.05
    Sodium Saccharin 0.2
    Sodium Hydroxide (10% Solution) 1.75
    Purified water to 100
  • S.N. 24 EXAMPLE 7 (Placebo) Formulation Thickened with Sodium Carboxymethylcellulose
  • [0066]
    Ingredient %
    Citric Acid 0.200
    ETDA Disodium 0.020
    FDC red #33 0.006
    Glycerin 20.000
    Sodium Carboxymethylcellulose 2.400
    Sodium benzoate 0.100
    Hydrogenated glucose (a thickener) 6.5
    Purified water to 100
  • S.N. 25 EXAMPLE 9 (Placebo) Formulation Thickened with Sodium Carboxymethylcellulose and Hydroxypropyl Methylcellulose
  • [0067]
    Ingredient %
    Dibasic Sodium Phosphate 0.030
    Sodium Carboxymethylcellulose 2.400
    Hydroxypropyl Methyl cellulose (F4M) 0.900
    Monobasic Potassium Phosphate 0.020
    Methyl Paraben 0.180
    Propyl Paraben 0.500
    Sodium Chloride 0.050
    Sorbitol 70% 30.000
    Purified water to 100
  • S.N. 26 EXAMPLE 11 (Placebo) Formulation Thickened with Sodium Carboxymethylcellulose
  • [0068]
    Ingredient %
    Sodium Benzoate 0.250
    FDC Yellow #6 0.008
    Sodium Saccharin 0.220
    Sodium Carboxymethylcellulose 2.800
    Hydrogenated Glucose 20.000
    Purified water to 100
  • S.N. 27 EXAMPLE 12 (Placebo) Formulation Thickened with Sodium Carboxymethylcellulose
  • [0069]
    Ingredient %
    Sodium Carboxymethylcellulose 2.400
    FDC Red #33 0.006
    Sodium Saccharin 0.240
    Sodium Chloride 0.050
    Purified water to 100
  • S.N. 28 EXAMPLE 13 Acyclovir Formulation Thickened with Sodium Carboxymethylcellulose and Microcrystalline Cellulose
  • [0070]
    Ingredient %
    Acyclovir 4.000
    Methyl Paraben 0.100
    Propyl Paraben 0.020
    Sodium Carboxymethylcellulose 2.400
    Peppermint Flavor 0.150
    Glycerin 20.000
    Microcrystalline Cellulose 0.900
    Sorbitol 70% 20.000
    Sodium Saccharin 0.30
    FDC Yellow #6 0.008
    Purified water to 100
  • S.N. 29 EXAMPLE 15 (Placebo) Formulation Thickened with Sodium Carboxymethylcellulose and Microcrystalline Cellulose
  • [0071]
    Ingredient %
    FDC Red #33 0.006
    Microcrystalline Cellulose 0.900
    Sodium Carboxymethylcellulose 2.400
    Methyl Paraben 0.200
    Propyl Paraben 0.050
    Sodium Saccharin 0.250
    Purified water to 100
  • S.N. 30 EXAMPLE 16 (Placebo) Formulation Thickened with Sodium Carboxymethylcellulose
  • [0072]
    Ingredient %
    FDC Red #33 0.007
    Saccharin Sodium 0.250
    Imitation Cherry Flavor 0.150
    Sodium Carboxymethylcellulose 2.800
    Methyl Paraben 0.220
    Purified water to 100
  • S.N.31 EXAMPLE 18 (Placebo) Formulation Thickened with Sodium Carboxymethylcellulose and Polyethylene Glycol
  • [0073]
    Ingredient %
    Butylhydroxy Toluene 0.200
    Sodium Carboxymethylcellulose 2.500
    Polyethylene Glycol 1500 25.000
    Methyl Paraben 0.200
    Purified water to 100
  • [0074]
    REFERENCE SAMPLES (Serial Nos. 32-37): The following commercially available formulations were obtained (Ser. Nos. 32-34). These were selected as examples of thick viscous liquid preparations suitable for pharmaceutical use.
  • [0075]
    S.N. 32: Corsym Antihistaminic Suspension: (manufactured by Ciba, Canada), containing phenylpropanolamine hydrochloride, chorpheniramine maleate, antifoam A, corn syrup, ethyl cellullose, flavoring, methyl and propyl paraben, polyethylene glycol, polysorbate 80, starch, vegetable oil, xantham gum, and water.
  • [0076]
    S.N. 33: Agarol Laxative Liquid (manufactured by Warner Lambert Co., Canada), containing mineral oil, glycerin, phenolphthalein, agar, sodium cyclamate, and water.
  • [0077]
    S.N. 34: Natural Honey
  • [0078]
    Also several non-commercial pharmaceutical formulations disclosed in prior patents were also prepared (Ser. Nos. 35-37) to determine whether the characteristics of the formulations (such as viscosity, semisolid character, non-spillability, ease of administration, storage stability) would be suitable for the drug delivery system of the invention. The formulations were as described in the patents, except the materials were prepared as placebos (without the active ingredient). The characteristics of the formulations should not be expected to be significantly different with the active ingredient. As to Tachon et al. (Nos. 36-37), the two formulations selected were closest to those in the examples herein in that they lacked xanthan gum and other extraneous ingredients.
  • [0079]
    S.N. 35: Sterling Patent (Gorman et al., U.S. Pat. No. 5,288,479), Example, Placebo:
    Ingredient %
    PEG-6-32 20.00
    (PEG 300/PEG 1500 = 1:1)
    Propylene Glycol 5.00
    Glycerin 5.00
    Sorbitol Solution, 70% 40.00
    Potassium Sorbate 0.300
    Benzoic Acid 0.100
    FD & C Red #33 0.010
    Cherry/Raspberry Flavor 0.094
    Calcium Saccharin 0.180
    Carrageenan 1.50
    Purified Water to 100
  • [0080]
    S.N. 36: Nestec Patent (Tachon et al., U.S. Pat. No. 5,300,302, Example 24, Placebo:
    Ingredient %
    Carbomer 974P 1.0
    Glycerol 15.0
    Sorbitol 15.0
    Methyl paraben 0.15
    Sodium saccarinate 0.2
    Purified water to 100
  • [0081]
    S.N. 37: Nestec Patent (Tachon et al., U.S. Pat. No. 5,300,302, Example 31, Placebo:
    Ingredient %
    Carbomer 974P 1.7
    Sodium hydroxide 0.79
    Sodium benzoate 0.2
    Sodium saccharinate 0.2
    Purified water to 100
  • [0082]
    VISCOSITY: To measure viscosity, a Brookfield Viscometer was used with a ‘C’ spindle with Helipath movement at 20 RPM and 20° C. Further details are given in Table 1.
  • [0083]
    SEMI-SOLID CHARACTER: If a material is a semisolid then it has a measurable yield value. Yield value was measured as a relative value for all the samples utilizing the shutting off motion of the Brookfield Viscometer (with dial gauge). Semisolid products in gel or other semisolid form have a significant yield value; thick liquids or suspensions do not. The character of the material can be confirmed by visual and tactile observation.
  • [0084]
    EASE OF ADMINISTRATION: Ease of administration is reflected both (a) in extrudability and (b) spreadability. Extrudability was measured by loading 8 ml of the product into a syringe having an orifice of about 5 mm or less, then pressing the product out through the orifice. Extrudability is the ease of extruding a product from a squeezable container through a small orifice onto a spoon. A product that is difficult to extrude under these conditions is unsuitable for administration from a squeezable container. Extrudability also reflects the ease of ingesting the formulation when the spoon is placed in the mouth and the tongue is used to remove the product cleanly from the spoon. Spreadability (levelling) was measured by observing the behavior of the product over 5 minutes to determine whether the material remains as a heap or tends to spread to the edges of the spoon. Spreadability is also important to the ability to measure and administer a predetermined dose (typically one teaspoon) of a formulation.
  • [0085]
    SPILL RESISTANCE-VIBRATION: Three components of spill resistance measured: vibrations, inversion, and tilting. As to vibration, a lab shaker with minor modification was used to demonstrate, quantitatively, the extent of non-spillability of the claimed products when shaken in the spoon. The lab shaker was modified to exhibit controlled horizontal motion of the spoon(s) attached. See FIG. 5A.
  • [0086]
    SPILL RESISTANCE-INVERSION: A custom-made platform was prepared to show the comparative spilling of the product from a spoon, when inverted (turned upside down).
  • [0087]
    SPILL RESISTANCE-TILTING: Measurements were made to determine the time at which the products tend to come off the spoon. The method used was to clamp spoons at a 90° angle and monitor the product sliding off the spoon. See FIG. 5B.
  • [0088]
    Results
  • [0089]
    The data generated on the above samples is presented in Tables 1 and 2. The data emphasizes the important properties and advantages of a semi-solid drug delivery system. Table 1 presents the physico-chemical characteristics of the test samples and reference samples. Table 2 presents the spill resistance data.
    TABLE 1
    PHYSICO-CHEMICAL CHARACTERISTICS
    Viscosity Semi-solid Ease of
    No. Product/Base Description (cps) Characteristics Administration**
    A. Test samples (From Ross Patent Application)
    21 PEG/PG Base w/Pseudoephed. 36,500 Yes +
    22 CMC/PG/Gly base w/APAP 38,500 Yes ++
    23 Carbomer/NaOH w/DMH Br 13,500 Yes ++
    24 CMC/Gly/Hyd.Glucose base(Placebo) 43,500 Yes ++
    25 CMC/HPMC/Sorbitol base(Placebo) 45,000 Yes ++
    26 CMC/Hyd. Glucose base (Placebo) 48,000 Yes +++
    27 CMC base (Placebo) 28,000 Yes ++
    28 CMC/MCC/Glyc/Sorb.base w/Acyclovir 45,000 Yes +++
    29 CMC/MCC Base (Placebo) 24,500 Yes ++
    30 CMC Base (Placebo) 38,000 Yes ++
    31 CMC/PEG Base (Placebo) 42,500 Yes ++
    B. Reference Samples (Commercial products or patented examples)
    32 Corsym Suspension 3,500 No ++++
    33 Agarol Laxative Liquid 2,700 No ++++
    34 Natural Unpasteurized Honey 22,850 No ++++
    35 PEG 6-32/Carageenen base(Placebo): Sterling 16,500 Yes (Phase separation)
    Pat# 5,200,479
    36 Carbomer/Glyc/Sorb: Ex# 24(Placebo), Nestec 400 No ++++
    Pat# 5,300,302
    37 Carbomer/Glyc/Sorb/NaOH: Ex#31(Placebo), Yes Yes −−
    Nestec Pat# 5,300,302

    *Viscosity measurements done by Brookfield Viscometer, Model BVII, using ‘C’ spindle at 20 rpm and 20 deg C. except in Nos. 8 & 17, where the ‘C’ spindle could not be used due to instrumental error. The viscosity result shown above are extrapolated from measurements using ‘D’ spindle.

    **Ease of administration is demonstrated through the extrudability of the product from tube onto spoon and then measurability/spreadibility of the product in the spoon, as discussed in the text. Grades ‘+’ to ‘+++’ indicate the products have acceptable
    # extrudability/measurability, whereas product marked ‘++++’ behave like a thick # liquid which has a tendency to spill off the spoon on overfilling. Products marked ‘−−’ indicate the products do not extrude as uniform gel and also do not have
    # spreading characteristics.
  • [0090]
    A summary of the results of Table 1 is as follows:
      • (a) The test samples (S.N. 21-31) all had a viscosity when made within the range of 13,500-45,000 at 20 degrees C. and 20 rpm. Reference sample S.N. 32, 33, and 36 all had very low viscosity, below 3500 cps.
      • (b) The test samples all had semisolid characteristics. Reference samples S.N. 32-34 and 36 did not. Viscosity was independent of yield value (semi-solid character) so that a product with the same viscosity can be distinguished as a liquid or semi-solid.
  • [0093]
    (c) The test samples all rated “+” to “+++” for ease of administration (extrudability and spreadability). The samples of S.N. 21-31 have a semi-solid gel-like consistency which can be squeezed out of a tube to the spoon. However, they are thick and the leveling is somewhat slow. This represents an intermediate level of ease of administration and measurability of dosage by spoon-leveling indication. Reference samples S.N. 35 and 36 lacked ease of administration. Ease of administration was also observed to be a characteristic somewhat independent of the other measured characteristics. For example, it may be difficult to administer a unit dose of a thick liquid because the liquid will dribble from the container instead of extrude as a cohesive mass.
    TABLE 2
    SPILL RESISTANCE DATA
    Time to Spill (min) Non-spill
    No. Product/Base Composition On Vibration On Inversion On Tilting at 90° Characteristics
    A. Test Samples (From Ross Patent Application)
    21 PEG/PG base w/Pseudoephed. 15 >20 1:30 yes
    22 CMC/PG/Glyc base w/APAP >60 2:40 3:51 yes
    23 Carbomer/NaOH base w/DMH Br 30 >20 0:40 yes
    24 CMC/Glyc/Hyd.Glucose base (Placebo) >60 3:40 0:58 yes
    25 CMC/HPMC/Sorbitol base (Placebo) >60 >20 7 yes
    26 CMC/Hyd.Glucose base (Placebo) >60 4:10 0:56 yes
    27 CMC base (Placebo) >60 0:31 0:22 yes
    28 CMC/Glyc/MCC/Sorb. base w/Acyclovir >60 >20 >20 yes
    29 CMC/MCC base (Placebo) >60 0:27 0:20 yes
    30 CMC Base (Placebo) >60 >1:15   0:45 yes
    31 CMC PEG Base (Placebo) >60 >20 >20 yes
    B. Reference Samples (commercial products or patented examples)
    32 Corsym Suspension 1 Immediately Immediately no
    33 Agarol Laxative Liquid 0.5 Immediately Immediately no
    34 Natural Unpasteurized Honey 31 Immediately Immediately no
    35 PEG6-32/Carageenen base(Placebo) Sterling 33 Immediately 0:11 no
    # 5,288,479
    36 Carbomer/Glyc/Sorb base: Ex# 24(Placebo) Immediately Immediately Immediately no
    Nestec # 5,300,302
    37 Carbo./Glyc/Sorb/NaOH base: Ex# 31(placebo) >60 >20 15 yes, but too stiff
    Nestec # 5,300,302

    Equipment Used: Lab Shaker, Model: BURREL WRIST SHAKER, modified to provide horizontal shaking.

    Frequency: 28 per minute Speed setting:Amplitude: Speed #1:0.5″, #2:0.75, #3:1:0, #4:1.25, #5:1.5

    Vibrating Time: 10 minutes on each speed beginning from speed #2

    Spoon: White plastic spoon round, deep (dia. = 11/2″ (4 cm) depth. = 7/16 (1.2 cm) with 8 ml capacity.

    Inversion and tilting resistance were monitored for 20 minutes.
  • [0094]
    The results of Table 2 are summarized as follows: The Ross test samples all had non-spill characteristics. Reference samples S.N. 32-36 lacked non-spill characteristics and lacked spill resistance. These characteristics were observed to be largely independent of those reported in Table 1. In particular, for the test samples, the spill start time on vibration was 15 minutes or more, the spill start time on inversion was half a minute or more, and the spill start time on tilting at 90 degrees was at least about 30 seconds. The only prior art reference sample that matched this non-spill characteristic was S.N. 37, but it was too stiff for ease of administration (see above).
      • a) By Vibration: The Ross examples are non-spilling for as much as 15-60 minutes at a shaking speed of 1.5″ amplitude w/28 per sec. frequency. In contrast, the marketed products like Corsym (thick suspension), Agarol Laxative Liquid (gel like product), and natural honey tend to spill-off the spoon in less than one to about 30 minutes.
      • b) By Inversion and Tilting: Many of the Ross test non-spill base products do not spill off the spoon when inverted upside down for as long as 20 minutes, whereas most of the other prior art samples spill off immediately. It was also observed that the test products do not leave residual content of the drug product on the spoon, and are not likely to do so when ingested by mouth. This can be correlated to the assurance of full dosage administration. In contrast, the thick liquids do not come off cleanly.
  • [0097]
    As to S.N. 35 (Gorman et al.), the preparation when completed as per the process mentioned in the patent does not form a uniform gel. Instead, water starts separating out on storage within a few hours. This renders the product not suitable for uniform dosage when the active component will be incorporated, nor is it physically stable. Also, the spill resistance qualities are not met, with special reference to vibration and invertibility. This is different than the qualities covered for the non-spill formulations of the invention.
  • [0098]
    As to Tachon et.al., S.N. 36 turned out to be a thick liquid and not a semisolid gel, and it lacked spill-resistance as claimed here. S.N. 37 on the other hand yielded a very stiff consistency product which is not easily squeezable from a tube/dispenser and is also non-spreading. Thus this product is inconsistent, and is not easy to administer or measure as to dose.
  • [0099]
    CONCLUSION: Non-spill formulations according to the Ross invention and the prior art products exhibit particular rheological properties which may be measured as a proxy for administration to dexterity-impaired patients. The test methods described herein are a useful way to determine whether a formulation is suitable for use as a spill-resistant formulation according to the invention, as a non-spill formulation or otherwise. Examples 21-31 are very thick, and examples 32-37 have other properties that make them unsuitable as a drug delivery system for children and geriatric and motor-disordered patients. These patients find it difficult to keep the hands steady and hence are likely to spill the drug product from the spoon before ingesting. In formulations according to the Ross application, the non-spill base and pharmaceutical formulations offer an absence of spilling despite invertibility.
  • EXAMPLES 38-45
  • [0100]
    In these experiments, spill resistant formulations were prepared containing dextromethorphan hydrobromide (DM), guafenesin (GU), acetaminophen (AC), or pseudoephedrine hydrochloride (PE), in a cellulose-based gel and in a carbomer gel according to the invention. The formulations are given in Table 3.
    TABLE 3
    EXAMPLES
    INGREDIENT % 38 39 40 41 42 43 44 45
    Active DM GU AC PE DM GU AC PE
    0.30 2.00 3.20 0.60 0.30 2.00 3.20 0.6
    Sodium Carboxymethylcellulose 0.90 0.90 0.90 0.90
    Microcrystalline 0.90 0.90 0.90 0.90
    cellulose
    Propylene glycol 25.00 25.00 25.00 25.00
    Carbopol 974 0.50 0.25 0.25 1.00
    Glycerin 30.00 30.00 30.00 30.00 50.00 50.00 50.00 50.00
    FD&C Yellow #6 0.01 0.01 0.01 0.01
    FD&C Red #40 0.005 0.005 0.005 0.005
    Sodium 0.30 0.30 0.30 0.30
    saccharin
    Methyl paraben 0.20 0.20 0.20 0.20 0.22 0.22 0.22 0.22
    Sorbitol 70% 10.00 10.00 10.00 10.00
    Purified water 57.39 55.69 54.49 57.09 23.975 22.525 21.325 23.175
    pH 6.08 6.06 6.08 6.41 6.72 6.63 6.55 6.25
    Storage Data
    Viscosity (initial) 11950 11100 12175 11975 7050 9550 9800 10625
    Viscosity (40°) 20560 22250 9520 19354 8370 9350 8650 12100
  • [0101]
    Each of these formulations had suitable characteristics of viscosity, spill-resistance, and ease of administration. They were semi-solids. They were freer-flowing gels than the compositions of Ross. They all had pH between about 6 and about 7. Examples 42-45 were essentially free from sodium except for small quantities of sodium oxide used to adjust the pH.
  • [0102]
    In addition, the formulations were subjected to stability testing for several months at room temperature and accelerated stability conditions with elevated temperature and elevated humidity (40 degrees C., 75% relative humidity). In all cases, the formulations homogeneous at the outset and after stability testing. Viscosity remained suitably constant. Table 3 gives the viscosity data for stored formulation after storage for 3 months at elevated temperature (40 degrees C.) and 75% humidity.
  • [0103]
    An additional unexpected advantage of Example 44 was that the Carbopol had a very effective taste-masking effect, making the formulation palatable despite the bitterness of acetaminophen. This feature permits the avoidance of other taste-masking agents.
    TABLE 4
    Spill time
    Active (sec)
    No. Agent Thickener 90° Invert Spreadability Semisolid?
    38 DM CMC/MCC 3 4 +++++ Yes
    39 GU 3 4 +++++ Yes
    40 AC 2 3 +++++ Yes
    41 PE 2 3 +++++ Yes
    42 DM Carbopol 1 2 +++++ Yes
    43 GU 2 3 +++++ Yes
    44 AC 2 3 +++++ Yes
    45 PE 2 3 +++++ Yes
  • [0104]
    Spreadability is given on a scale where:−− means very stiff semi-solid, + means less stiff semi-solid, 2+, 3+, 4+, and 5+ indicate increasing spreadability.
  • [0105]
    As can be seen from Table 4, the inventive formulations are semi-solids, unlike the liquid formulations of the prior art. The inventive formulations have very high spreadability, at least as high as honey. They do not spill from a spoon immediately on tilting or inversion, as do the liquids, but they do come off within several seconds, much faster than the non-spill formulations of Ross.
  • [0106]
    In addition, the formulations were tested at high frequency vibration similar to the tremors of Parkinsonian patients. At amplitudes of 1 to 2 inches, and frequency of 120-240 per minute (4/sec), the inventive formulations do not spill. This spill-resistance is better than honey at room temperature.
  • [0107]
    Each reference cited herein is incorporated by reference in its entirety as if specifically incorporated by reference. The embodiments illustrated and discussed in this specification are intended only to teach those skilled in the art the best way known to the inventors to make and use the invention. Nothing in this specification should be considered as limiting the scope of the present invention. Modifications and variations of the above-described embodiments of the invention are possible without departing from the invention, as appreciated by those skilled in the art in light of the above teachings. It is therefore to be understood that, within the scope of the claims and their equivalents, the invention may be practiced otherwise than as specifically described.

Claims (13)

  1. 1. A method for administering a pharmaceutically active agent to a patient in need of the pharmaceutically active agent, comprising the step of administering a therapeutically effective amount of the active agent in a pharmaceutical composition comprising an effective amount of a pharmaceutical agent in a suitable vehicle comprising a liquid base and a thickening agent, the formulation consisting of mutually compatible components and having the following properties:
    an initial viscosity within the range of about 7,500 to about 12,500 cps using a Brookfield Viscometer with a ‘C’ spindle with Helipath movement at a spindle speed of 20 rpm and 20-25 degrees C.,
    a viscometric yield value of a semi-solid
    a spill resistant consistency permitting the composition to be squeezed by light manual pressure though a channel of about 1-1.5 mm, to spread in a spoon bowl sufficiently quickly for accurate measurement, and to remain in the spoon bowl without spilling for at least about one second and less than about 20 seconds on spoon tilting at 90 degrees, and for at least about 30 seconds upon spoon vibration at a frequency of about 120/minute,
    homogeneity such that the components do not separate under conditions of use, and
    a storage stability such that the foregoing properties are retained for at least three months of storage at elevated temperature, with viscosity remaining within a range of 50% less to 100% more than the initial viscosity,
    wherein said thickening agent comprises components selected from the group consisting of cellulose derivatives in an amount of less than about 2 weight % by volume, and water-soluble carboxyvinyl polymer in an amount less than 1 weight % by volume.
  2. 2. The method of claim 1 wherein the composition has a viscosity between about 7,500 and about 25,000 cps after storage for three months at a temperature of 40 degrees C. and 75% humidity.
  3. 3. The method of claim 1 wherein the composition has an initial viscosity of between about 7500 and about 12,500 cps after storage.
  4. 4. The method of claim 1 wherein the thickening agent is from about 0.25 to less than 1 weight % water-soluble carboxyvinyl polymer.
  5. 5. The method of claim 1 wherein the liquid base comprises glycerin and sorbitol.
  6. 6. The method of claim 1 wherein the thickening agent comprises water-soluble carboxyvinyl polymer in an amount of from about 0.25 to about 1.0 weight % by volume.
  7. 7. The method of claim 1 having a spill-resistant consistency permitting the composition to remain in the spoon bowl without spilling for from about 1 second to about 4 seconds on spoon inversion and on spoon tilting at 90 degrees.
  8. 8. The method of claim 1 wherein the pharmaceutical agent is selected from the group consisting of an analgesic, non-steroidal anti-inflammatory, antihistamine, cough suppressant, expectorant, bronchodilator, anti-infective, CNS active drug, cardiovascular drug, antineoplastic, cholesterol-lowering drug, anti-emetic, vitamin, mineral supplement and fecal softener.
  9. 9. The method of claim 1 wherein the pharmaceutical agent is selected from the group consisting of acetaminophen, aspirin, ibuprofen, diphenhydramine, dextromethorphan, guafenesin, pseudoephedrine, carbidopa, levodopa, terfenadine, ranitidine, ciprofloxacin, triazolam, fluconazole, propranolol, acyclovir, fluoxetine, enalapril, diltiazem, lovastatin and a pharmaceutically acceptable salt or ester thereof.
  10. 10. The method of claim 1 wherein the storage stability extrapolates to at least two years shelf life at room temperature.
  11. 11. The method of claim 1 wherein the patient is dexterity-impaired.
  12. 12. The method of claim 1 wherein the patient is selected from the group consisting of young children, the infirm, and elderly adults with motor disabilities.
  13. 13. The method of claim 1 wherein the patients have tremors.
US10653149 1998-06-03 2003-09-03 Method for administering a spill resistant pharmaceutical system Abandoned US20050042237A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US09089360 US6071523A (en) 1998-06-03 1998-06-03 Spill resistant pharmaceutical compositions in semi-solid form
US09549148 US6399079B1 (en) 1998-06-03 2000-04-13 Spill resistant pharmaceutical compositions in semi-solid form
US10052462 US6656482B2 (en) 1998-06-03 2002-01-23 Spill resistant pharmaceutical system
US10653149 US20050042237A1 (en) 1998-06-03 2003-09-03 Method for administering a spill resistant pharmaceutical system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10653149 US20050042237A1 (en) 1998-06-03 2003-09-03 Method for administering a spill resistant pharmaceutical system
US12603831 US20100063010A1 (en) 1998-06-03 2009-10-22 Method for administering a spill resistant pharmaceutical system

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10052462 Continuation US6656482B2 (en) 1998-06-03 2002-01-23 Spill resistant pharmaceutical system

Publications (1)

Publication Number Publication Date
US20050042237A1 true true US20050042237A1 (en) 2005-02-24

Family

ID=22217234

Family Applications (6)

Application Number Title Priority Date Filing Date
US09089360 Expired - Lifetime US6071523A (en) 1998-06-03 1998-06-03 Spill resistant pharmaceutical compositions in semi-solid form
US09548927 Expired - Lifetime US6355258B1 (en) 1998-06-03 2000-04-13 Method for formulating spill resistant pharmaceutical compositions in semi-solid form
US09549148 Expired - Lifetime US6399079B1 (en) 1998-06-03 2000-04-13 Spill resistant pharmaceutical compositions in semi-solid form
US10052462 Expired - Fee Related US6656482B2 (en) 1998-06-03 2002-01-23 Spill resistant pharmaceutical system
US10653149 Abandoned US20050042237A1 (en) 1998-06-03 2003-09-03 Method for administering a spill resistant pharmaceutical system
US12603831 Abandoned US20100063010A1 (en) 1998-06-03 2009-10-22 Method for administering a spill resistant pharmaceutical system

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US09089360 Expired - Lifetime US6071523A (en) 1998-06-03 1998-06-03 Spill resistant pharmaceutical compositions in semi-solid form
US09548927 Expired - Lifetime US6355258B1 (en) 1998-06-03 2000-04-13 Method for formulating spill resistant pharmaceutical compositions in semi-solid form
US09549148 Expired - Lifetime US6399079B1 (en) 1998-06-03 2000-04-13 Spill resistant pharmaceutical compositions in semi-solid form
US10052462 Expired - Fee Related US6656482B2 (en) 1998-06-03 2002-01-23 Spill resistant pharmaceutical system

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12603831 Abandoned US20100063010A1 (en) 1998-06-03 2009-10-22 Method for administering a spill resistant pharmaceutical system

Country Status (7)

Country Link
US (6) US6071523A (en)
EP (3) EP1082103B1 (en)
JP (2) JP4240814B2 (en)
CA (1) CA2333405C (en)
DE (3) DE69939792D1 (en)
ES (1) ES2253920T3 (en)
WO (1) WO1999062498A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071523A (en) * 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
WO2000025765A3 (en) * 1998-10-30 2000-08-03 Bayer Ag Aqueous drug formulation for oral application
EP1163901B1 (en) * 1999-02-26 2008-09-10 SHIONOGI & CO., LTD. Chewable soft capsules having improved administration properties and process for producing the same
US20020148852A1 (en) * 2001-04-17 2002-10-17 Schultz Joseph P. Liquid dispensing and administering system
US20090227943A1 (en) * 2001-04-17 2009-09-10 Schultz Joseph P Liquid Dispensing and Administering System
DK1411899T3 (en) * 2001-08-01 2009-06-02 Novartis Ag Taste Masking composition
US20030060422A1 (en) 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
US20030235618A1 (en) * 2001-10-22 2003-12-25 Taro Pharmaceutical Industries Ltd. Taste masking spill-resistant formulation
US20050143471A1 (en) * 2001-10-22 2005-06-30 Shen Gao Taste masking spill-resistant formulation
DE60239752D1 (en) * 2001-10-22 2011-05-26 Taro Pharma Ind The taste masking formulation leakproof
EP1383687B1 (en) * 2001-10-22 2009-08-19 Taro Pharmaceutical Industries Limited Container for dispensing spill-resistant formulations
US7374046B1 (en) * 2002-02-20 2008-05-20 O'brien John J Disposable food delivery apparatus
WO2003105804A1 (en) * 2002-06-17 2003-12-24 Taro Pharmaceuticals U.S.A, Inc. Ibuprofen suspension
CA2540869C (en) * 2003-10-28 2013-04-30 Taro Pharmaceuticals U.S.A., Inc. Spill resistant formulations containing clays
US6851574B1 (en) * 2003-12-23 2005-02-08 Timothy G. Traynor Spoon
WO2005076829A3 (en) * 2004-02-05 2005-11-24 Satish Asotra Stable loratadine spill resistant formulation
DK1758557T3 (en) 2004-05-11 2011-10-24 Egalet Ltd Swellable dosage form comprising gellan gum
US6928870B1 (en) 2004-05-18 2005-08-16 Lapform Products, Inc. Spice storage and dispensing spoon
US7799331B2 (en) * 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate
WO2007022105A3 (en) 2005-08-12 2007-09-27 Nagesh R Palepu Stable pharmaceutical compositions, processes for making the same, and methods of their use
US20070098785A1 (en) * 2005-11-02 2007-05-03 Tim Clarot Medicant delivery system and device
WO2007087344A3 (en) 2006-01-25 2007-12-13 Taro Pharmaceuticals Usa Inc Anti-histamine compositions and use thereof
US20090023638A1 (en) * 2006-02-06 2009-01-22 Taro Pharmaceuticals North American, Inc. Spill resistant antibiotic formulations
JP5226661B2 (en) * 2006-04-06 2013-07-03 ターロ ファーマシューティカルズ ノース アメリカ インコーポレイテッド Novel spill resistant formulation comprising a hydrocolloid polymer
US9237815B2 (en) 2006-11-07 2016-01-19 Dixie Consumer Products Llc Cutlery dispenser and method of dispensing cutlery
KR20080076667A (en) 2007-02-15 2008-08-20 주식회사 중외제약 Thixotropic pharmaceutical compositions
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US8771643B2 (en) * 2008-01-04 2014-07-08 Schabar Research Associates Llc Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
CA2765033A1 (en) * 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US8105430B2 (en) * 2009-06-30 2012-01-31 Alberta Research Council Inc. Aircraft anti-icing fluids formulated with nanocrystalline cellulose
GB0913295D0 (en) 2009-07-30 2009-09-02 Norgine Bv Improvements in and relating to pharmaceutical compositions
US20110186597A1 (en) * 2010-01-29 2011-08-04 Thomas Schaefer Baby food spoon
US9295344B2 (en) 2010-03-19 2016-03-29 Dixie Consumer Products Llc Cutlery utensil dispenser
WO2011156485A3 (en) 2010-06-08 2012-04-26 Dixie Consumer Products Llc System and method for holding cutlery together
US20110315720A1 (en) * 2010-06-28 2011-12-29 Unicep Packaging, Inc. Dispenser with twist lock fitting
US9345340B2 (en) 2010-12-10 2016-05-24 Dixie Consumer Products Llc Dispensing mechanism for utensil dispenser and related methods
CA2819646A1 (en) * 2010-12-14 2012-06-21 Dixie Consumer Products Llc Belt drive for dispensing cutlery and related methods
US8844424B2 (en) 2011-08-17 2014-09-30 Lwrc International Llc Bolt carrier and bolt for gas operated firearms
US8950312B2 (en) 2011-08-17 2015-02-10 Lwrc International Llc Bolt carrier and bolt for gas operated firearms
US9439518B2 (en) 2011-08-19 2016-09-13 Dixie Consumer Products Llc Cutlery dispenser
USD708318S1 (en) * 2011-09-02 2014-07-01 Oms Investments, Inc. Dosing spoon
GB201117858D0 (en) * 2011-10-17 2011-11-30 Norbrook Lab Ltd Paste
CN103957894A (en) 2011-10-19 2014-07-30 R.P.谢勒技术有限公司 Two phase pharmaceutical delivery system
US8950635B2 (en) 2012-03-14 2015-02-10 Honey Bee Babies, Llc Unitary product-dispensing container having a combined cap and feeding/ dosing dispenser
WO2013142482A1 (en) 2012-03-20 2013-09-26 Particle Dynamics International, Llc Gelling agent-based dosage form
GB201211742D0 (en) * 2012-07-03 2012-08-15 Eaton Power Quality S A S Grouping power sources and power loads to groups that share similar properties
US9506711B2 (en) 2012-07-31 2016-11-29 Lwrc International Llc Barrel nut assembly and method to attach a barrel to a firearm using such assembly
US9816546B2 (en) 2012-07-31 2017-11-14 Lwrc International Llc Barrel nut assembly and method to attach a barrel to a firearm using such assembly
US9140506B2 (en) 2012-07-31 2015-09-22 Lwrc International Llc Firearm receiver assembly
US9266646B2 (en) 2012-09-07 2016-02-23 Dixie Consumer Products Llc Cutlery utensil dispensing package
US8943947B2 (en) 2013-03-15 2015-02-03 Lwrc International Llc Firearm buffer system and buttstock assembly
CA2919249A1 (en) 2013-07-25 2015-01-29 Dixie Consumer Products Llc Cutlery dispenser and related methods
CA2920035A1 (en) 2013-08-08 2015-02-12 Dixie Consumer Products Llc Front loading cutlery dispenser
US9332861B2 (en) 2013-08-19 2016-05-10 Dixie Consumer Products Llc Cutlery dispenser and methods of use
US9506702B2 (en) 2014-01-10 2016-11-29 Jv Precision Machine Company Externally loading semi-automatic firearm with integral or non-removable feeding device
JP2017513672A (en) 2014-04-11 2017-06-01 ディクシー コンスーマー プロダクツ エルエルシー Forward propulsion cutlery dispensing device
CA2991719A1 (en) * 2015-07-09 2017-01-12 Uniwell Laboratories Llc Pharmaceutical compositions

Citations (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1466043A (en) * 1921-09-12 1923-08-28 Graham John Gauge
US1544232A (en) * 1923-11-10 1925-06-30 Jr William C Huntoon Collapsible tube
US2252119A (en) * 1940-02-03 1941-08-12 Henry N Edmonds Infant's or invalid's feeding spoon
US2556571A (en) * 1945-11-19 1951-06-12 William P Bobbs Metering spring closure for dispensing tubular containers
US2559070A (en) * 1948-10-21 1951-07-03 Goldberg Louis Dispensing closure for collapsible containers with delayed-action, self-closing valve
US3104032A (en) * 1960-08-18 1963-09-17 American Can Co Attachment for cutting a collapsible tube and dispensing material therefrom
US3116152A (en) * 1959-01-22 1963-12-31 Elmer L Smith Baby food container and spoon combined
US3133679A (en) * 1961-04-05 1964-05-19 Frank E Brown Liquid dispensing device
US3145886A (en) * 1962-04-10 1964-08-25 Kenneth A Goodwin Self-closing caps for collapsible tubes
US3383018A (en) * 1966-07-15 1968-05-14 American Can Co Dispensing container and overcap
US3395835A (en) * 1966-10-20 1968-08-06 Phil K. Tarran Automatic dispensing means
US3493146A (en) * 1967-05-18 1970-02-03 Corco Inc Liquid container with dispensing valve
US3767784A (en) * 1970-12-01 1973-10-23 S Gluck Composition for the protection and treatment of injured body tissue and method of utilizing the same
US3797704A (en) * 1972-10-17 1974-03-19 Conserv Resources Inc Safety closure
US3920819A (en) * 1974-12-02 1975-11-18 Lilly Co Eli Nonaqueous vehicle for oral pharmaceutical suspensions
US3927205A (en) * 1973-04-09 1975-12-16 Takeda Chemical Industries Ltd Aqueous suspension of pharmaceuticals
US4091965A (en) * 1976-06-22 1978-05-30 Gerico, Inc. Combined feeding spout and cap attachment
US4221788A (en) * 1977-04-29 1980-09-09 Byk Gulden Lomberg Chemische Fabrik Gmbh 2-(Optionally-substituted)benzylperhydroazepines for analgesia and lowering blood pressure
US4284649A (en) * 1977-11-22 1981-08-18 Wiczer Sol B Thickened gelatinous edible alcoholic medicated carrier
US4305933A (en) * 1980-03-10 1981-12-15 Wiczer Sol B Thickened gelatinous edible alcoholic medicated carrier
US4361580A (en) * 1980-06-20 1982-11-30 The Upjohn Manufacturing Company Aluminum ibuprofen pharmaceutical suspensions
US4371580A (en) * 1982-01-26 1983-02-01 Morrison Company, Inc. Three-ply belting material
US4383993A (en) * 1980-05-30 1983-05-17 University Of Kentucky Research Foundation Nasal dosage forms containing natural female sex hormones
US4394390A (en) * 1979-08-03 1983-07-19 University Of Kentucky Research Foundation Nasal dosage forms of propranol
US4427681A (en) * 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
US4511068A (en) * 1982-01-19 1985-04-16 Gap Gesselschaft Fuer Auswertungen Und Patente Ag Dispenser for paste-like products
US4540572A (en) * 1983-08-29 1985-09-10 Mepha Ag Gel-like ointment containing indometacin
US4576645A (en) * 1984-12-06 1986-03-18 Block Drug Co., Inc. Whipped gel composition
US4593048A (en) * 1981-09-28 1986-06-03 Nitto Electric Industrial Co., Ltd. Base composition for external preparations, pharmaceutical composition for external use and method of promoting percutaneous drug absorption
US4651905A (en) * 1985-06-26 1987-03-24 Anchor Hocking Corporation Dispenser package
US4685593A (en) * 1985-05-08 1987-08-11 Isaias Loukos Feeder for highly abrasive materials
US4724615A (en) * 1986-11-17 1988-02-16 Product Resources International, Inc. Metered dosage spoon
US4761400A (en) * 1985-01-15 1988-08-02 Jouveinal S.A. Laxative composition based on lactulose and its preparation process
US4830222A (en) * 1986-01-28 1989-05-16 Read Avis O Combination spoon and food container
US4883660A (en) * 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
US4957226A (en) * 1987-06-05 1990-09-18 Wells Manufacturing Automatic food dispensing method, apparatus and utensil
US4964538A (en) * 1988-07-20 1990-10-23 Colgate-Palmolive Company Package for flowable material
US4972007A (en) * 1987-12-11 1990-11-20 Wolff Walsrode Ag Use of cellulose derivatives in drilling fluids
US5137183A (en) * 1990-08-02 1992-08-11 Mikulec Timothy L Compressible feeding apparatus
US5154926A (en) * 1990-02-06 1992-10-13 Showa Yakuhin Kako Co., Ltd. Acetaminophen or phenobarbital syrup composition
US5221488A (en) * 1988-08-01 1993-06-22 Henkel Kommanditgesellschaft Auf Aktien Process for dosing paste-form detergents
US5288479A (en) * 1989-01-17 1994-02-22 Sterling Drug, Inc. Extrudable elastic oral pharmaceutical gel compositions and metered dose dispensers containing them and method of making and method of use thereof
US5300302A (en) * 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
US5305928A (en) * 1993-06-04 1994-04-26 Roberto Verdaguer Squeezable feeding container
US5385747A (en) * 1992-07-23 1995-01-31 Mama Tish's Italian Specialties, Inc. Process for making a fruit gel composition in squeeze container
US5602182A (en) * 1995-01-30 1997-02-11 American Home Products Corporation Taste masking pseudoephedrine HCL containing liquids
US5881926A (en) * 1993-03-11 1999-03-16 Taro Pharmaceutical Industries, Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6071523A (en) * 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
US6102254A (en) * 1993-03-11 2000-08-15 Taro Pharmaceutical Industies Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
US6586499B2 (en) * 2000-12-19 2003-07-01 Bausch & Lomb Incorporated Water-soluble blocking wax formulation
US20060035804A1 (en) * 2003-02-10 2006-02-16 Josef Penninger Use of cellulose derivatives as foam regulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB798900A (en) 1955-12-27 1958-07-30 Woodrow Stevens Wilson Improvements in or relating to dispensing closures for containers
JPS45798Y1 (en) 1966-07-19 1970-01-13
DE2145618C3 (en) * 1971-09-13 1975-04-30 Messerschmitt-Boelkow-Blohm Gmbh, 8000 Muenchen
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
US5919481A (en) * 1996-06-28 1999-07-06 Ncneil-Ppc, Inc. Fill material for soft gelatin pharmaceutical dosage form
DE69730166D1 (en) 1996-10-08 2004-09-09 Corning Inc A device for suppression of the zeroth order beam from an illuminated with polarized light hologram
EP0839517A3 (en) * 1996-11-01 2003-10-01 Unilever N.V. Dental product
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US20050282859A1 (en) * 2004-06-04 2005-12-22 Thor Karl B Dual acting SNRI-NMDA antagonists for the treatment of genitourinary disorders

Patent Citations (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1466043A (en) * 1921-09-12 1923-08-28 Graham John Gauge
US1544232A (en) * 1923-11-10 1925-06-30 Jr William C Huntoon Collapsible tube
US2252119A (en) * 1940-02-03 1941-08-12 Henry N Edmonds Infant's or invalid's feeding spoon
US2556571A (en) * 1945-11-19 1951-06-12 William P Bobbs Metering spring closure for dispensing tubular containers
US2559070A (en) * 1948-10-21 1951-07-03 Goldberg Louis Dispensing closure for collapsible containers with delayed-action, self-closing valve
US3116152A (en) * 1959-01-22 1963-12-31 Elmer L Smith Baby food container and spoon combined
US3104032A (en) * 1960-08-18 1963-09-17 American Can Co Attachment for cutting a collapsible tube and dispensing material therefrom
US3133679A (en) * 1961-04-05 1964-05-19 Frank E Brown Liquid dispensing device
US3145886A (en) * 1962-04-10 1964-08-25 Kenneth A Goodwin Self-closing caps for collapsible tubes
US3383018A (en) * 1966-07-15 1968-05-14 American Can Co Dispensing container and overcap
US3395835A (en) * 1966-10-20 1968-08-06 Phil K. Tarran Automatic dispensing means
US3493146A (en) * 1967-05-18 1970-02-03 Corco Inc Liquid container with dispensing valve
US3767784A (en) * 1970-12-01 1973-10-23 S Gluck Composition for the protection and treatment of injured body tissue and method of utilizing the same
US3797704A (en) * 1972-10-17 1974-03-19 Conserv Resources Inc Safety closure
US3927205A (en) * 1973-04-09 1975-12-16 Takeda Chemical Industries Ltd Aqueous suspension of pharmaceuticals
US3920819A (en) * 1974-12-02 1975-11-18 Lilly Co Eli Nonaqueous vehicle for oral pharmaceutical suspensions
US4091965A (en) * 1976-06-22 1978-05-30 Gerico, Inc. Combined feeding spout and cap attachment
US4221788A (en) * 1977-04-29 1980-09-09 Byk Gulden Lomberg Chemische Fabrik Gmbh 2-(Optionally-substituted)benzylperhydroazepines for analgesia and lowering blood pressure
US4284649A (en) * 1977-11-22 1981-08-18 Wiczer Sol B Thickened gelatinous edible alcoholic medicated carrier
US4394390A (en) * 1979-08-03 1983-07-19 University Of Kentucky Research Foundation Nasal dosage forms of propranol
US4305933A (en) * 1980-03-10 1981-12-15 Wiczer Sol B Thickened gelatinous edible alcoholic medicated carrier
US4383993A (en) * 1980-05-30 1983-05-17 University Of Kentucky Research Foundation Nasal dosage forms containing natural female sex hormones
US4361580A (en) * 1980-06-20 1982-11-30 The Upjohn Manufacturing Company Aluminum ibuprofen pharmaceutical suspensions
US4593048A (en) * 1981-09-28 1986-06-03 Nitto Electric Industrial Co., Ltd. Base composition for external preparations, pharmaceutical composition for external use and method of promoting percutaneous drug absorption
US4511068A (en) * 1982-01-19 1985-04-16 Gap Gesselschaft Fuer Auswertungen Und Patente Ag Dispenser for paste-like products
US4371580A (en) * 1982-01-26 1983-02-01 Morrison Company, Inc. Three-ply belting material
US4427681A (en) * 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
US4540572A (en) * 1983-08-29 1985-09-10 Mepha Ag Gel-like ointment containing indometacin
US4576645A (en) * 1984-12-06 1986-03-18 Block Drug Co., Inc. Whipped gel composition
US4761400A (en) * 1985-01-15 1988-08-02 Jouveinal S.A. Laxative composition based on lactulose and its preparation process
US4685593A (en) * 1985-05-08 1987-08-11 Isaias Loukos Feeder for highly abrasive materials
US4651905A (en) * 1985-06-26 1987-03-24 Anchor Hocking Corporation Dispenser package
US4830222A (en) * 1986-01-28 1989-05-16 Read Avis O Combination spoon and food container
US4724615A (en) * 1986-11-17 1988-02-16 Product Resources International, Inc. Metered dosage spoon
US4957226A (en) * 1987-06-05 1990-09-18 Wells Manufacturing Automatic food dispensing method, apparatus and utensil
US4972007A (en) * 1987-12-11 1990-11-20 Wolff Walsrode Ag Use of cellulose derivatives in drilling fluids
US4964538A (en) * 1988-07-20 1990-10-23 Colgate-Palmolive Company Package for flowable material
US5221488A (en) * 1988-08-01 1993-06-22 Henkel Kommanditgesellschaft Auf Aktien Process for dosing paste-form detergents
US4883660A (en) * 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
US5288479A (en) * 1989-01-17 1994-02-22 Sterling Drug, Inc. Extrudable elastic oral pharmaceutical gel compositions and metered dose dispensers containing them and method of making and method of use thereof
US5154926A (en) * 1990-02-06 1992-10-13 Showa Yakuhin Kako Co., Ltd. Acetaminophen or phenobarbital syrup composition
US5137183A (en) * 1990-08-02 1992-08-11 Mikulec Timothy L Compressible feeding apparatus
US5300302A (en) * 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
US5385747A (en) * 1992-07-23 1995-01-31 Mama Tish's Italian Specialties, Inc. Process for making a fruit gel composition in squeeze container
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US5881926A (en) * 1993-03-11 1999-03-16 Taro Pharmaceutical Industries, Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
US6102254A (en) * 1993-03-11 2000-08-15 Taro Pharmaceutical Industies Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
US5305928A (en) * 1993-06-04 1994-04-26 Roberto Verdaguer Squeezable feeding container
US5602182A (en) * 1995-01-30 1997-02-11 American Home Products Corporation Taste masking pseudoephedrine HCL containing liquids
US6071523A (en) * 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
US6355258B1 (en) * 1998-06-03 2002-03-12 Taro Pharmaceutical Industries Ltd. Method for formulating spill resistant pharmaceutical compositions in semi-solid form
US6399079B1 (en) * 1998-06-03 2002-06-04 Taro Pharmaceutical Industries Ltd. Spill resistant pharmaceutical compositions in semi-solid form
US6586499B2 (en) * 2000-12-19 2003-07-01 Bausch & Lomb Incorporated Water-soluble blocking wax formulation
US20060035804A1 (en) * 2003-02-10 2006-02-16 Josef Penninger Use of cellulose derivatives as foam regulators

Also Published As

Publication number Publication date Type
EP1082103B1 (en) 2005-12-14 grant
DE69928927D1 (en) 2006-01-19 grant
US6399079B1 (en) 2002-06-04 grant
CA2333405A1 (en) 1999-12-09 application
CA2333405C (en) 2006-10-31 grant
EP2008649A1 (en) 2008-12-31 application
EP1632224A1 (en) 2006-03-08 application
JP2002516849A (en) 2002-06-11 application
US6071523A (en) 2000-06-06 grant
JP4240814B2 (en) 2009-03-18 grant
WO1999062498A1 (en) 1999-12-09 application
DE69939792D1 (en) 2008-12-04 grant
ES2253920T3 (en) 2006-06-01 grant
JP2009079053A (en) 2009-04-16 application
EP1082103A1 (en) 2001-03-14 application
EP1632224B1 (en) 2008-10-22 grant
DE69928927T2 (en) 2006-08-17 grant
US6656482B2 (en) 2003-12-02 grant
US20020168411A1 (en) 2002-11-14 application
US6355258B1 (en) 2002-03-12 grant
JP5161722B2 (en) 2013-03-13 grant
US20100063010A1 (en) 2010-03-11 application

Similar Documents

Publication Publication Date Title
US6184220B1 (en) Oral suspension of pharmaceutical substance
US6287596B1 (en) Quickly disintegratable compression-molded materials and process for producing the same
US4925675A (en) Erythromycin microencapsulated granules
US6696085B2 (en) Use of an acrylic type polymer as disintegrating agent
US6224905B1 (en) Biconvex rapidly disintegrating dosage forms
Siddiqui et al. Fast dissolving tablets: preparation, characterization and evaluation: an overview
US20020119196A1 (en) Texture masked particles containing an active ingredient
US5206025A (en) Porous pharmaceutical form and its preparation
US6550955B2 (en) Process for producing liquid dosage formulations of medicinal compounds on demand from tablets and capsules using a mixing cup with an abrasive interior surface
US5631023A (en) Method for making freeze dried drug dosage forms
US20030161879A1 (en) Tablets quickly disintegrating in mouth
US6027746A (en) Chewable soft gelatin-encapsulated pharmaceutical adsorbates
US6503955B1 (en) Pourable liquid vehicles
US6102254A (en) Pharmaceutical compositions in semisolid form and a device for administration thereof
US5881926A (en) Pharmaceutical compositions in semisolid form and a device for administration thereof
Zade et al. Formulation, evaluation and optimization of fast dissolving tablet containing tizanidine hydrochloride
US5712310A (en) Suspension of substantially water-insoluble drugs and methods of their manufacture
US5932235A (en) Jellied medicinal composition for oral administration
US5919481A (en) Fill material for soft gelatin pharmaceutical dosage form
US20050249676A1 (en) Pullulan capsules
US5916590A (en) Soft gelatin pharmaceutical dosage form
Chandrasekhar et al. The role of formulation excipients in the development of lyophilised fast-disintegrating tablets
WO2003030877A1 (en) Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer
US5300302A (en) Pharmaceutical composition in gel form in a dispensing package
US20080260837A1 (en) Physically stable aqueous suspensions of active pharmaceuticals